Table 2b.
Associations between ATM Promoter Methylation and Clinicopathological Features of Breast Cancer
| Characteristics | Case n=50 | ATM promoter methylation | p-value | ATM mRNA expression | Expression fold change | p-value | ||
|---|---|---|---|---|---|---|---|---|
| Present n=29 | Absent n=21 | n=17 | Down regulation n=9 | Up regulation n=8 | ||||
| Age(year) | ||||||||
| < 50years | 20 (40%) | 16 (80 %) | 4 (20%) | 0.01 | 6 (35%) | 6 (100%) | 0 (0%) | 0.009 |
| ≥ 50 years | 30 (60%) | 13 (43 %) | 17 (57 %) | 11 (65%) | 3 (33%) | 8 (67%)) | ||
| Histological type | ||||||||
| Non-ductal | 3 (6%) | 1 (33 %) | 2 (67%) | 0.379 | 2 (12%) | 0 (0%) | 2 (100%) | 0.206 |
| Ductal | 47 (94%) | 28 (60%) | 19 (40%) | 15 (88%) | 9 (60%) | 6 (40%) | ||
| Nodal involvement | ||||||||
| Negative | 9 (18%) | 3 (32%) | 6 (68%) | 0.098 | 3 (18%) | 2 (67%) | 1 (33%) | 1 |
| Positive | 41 (82%) | 26 (63%) | 15 (37%) | 14 (82%) | 7 (50%) | 7 (50%) | ||
| TNM Stage | ||||||||
| I/II(early) | 26 (52%) | 11 (42%) | 15 (58%) | 0.019 | 10 (59%) | 4 (40%) | 6 (60%) | 0.335 |
| III/IV(Advance) | 24 (48%) | 18 (75%) | 6 (25%) | 7 (41%) | 5 (71%) | 2 (29%) | ||
| Metastasis | ||||||||
| Yes | 3 (6%) | 2 (67%) | 1 (33%) | 0.754 | - | - | ||
| No | 47 (94%) | 27 (57%) | 20 (43%) | - | ||||
| Tumor size | ||||||||
| ≤20 mm | 10 (20%) | 3 (30%) | 7 (70%) | 0.045 | 4 (23.5%) | 1 (25%) | 3 (75%) | 0.294 |
| >20 mm | 40 (80%) | 26 (65 %) | 14 (35% | 13 (76.5%) | 8 (61.5%) | 5 (52.9%) | ||
| Menopausal status | ||||||||
| Pre | 11 (22%) | 7 (64%) | 4 (36%) | 0.668 | 3 (18%) | 3 (100%) | 0 (0%) | 0.206 |
| Post | 39 (78%) | 22 (56 %) | 17 (44%) | 14 (82%) | 6 (43 %)) | 8 (57.%) | ||